IRDAI is moving to tighten eligibility criteria for insurance manufacturing licenses, reserving them for promoter-led entities with long-term commitment structures. The shift effectively blocks venture-capital-backed InsurTechs such as Onsurity and Loop Health from obtaining their own insurer licenses, pushing them instead toward distribution-only models, according to Techshots reporting on September 20, 2026.
What IRDAI is changing
The proposed tightening targets the ownership and governance structure of applicants seeking to manufacture insurance products. Under the new framework, manufacturing licenses would be reserved for entities where promoters hold a controlling stake and demonstrate long-term operational commitment. VC-funded startups, where ownership is dispersed across multiple funding rounds and investor interests may diverge from policyholder protection, would no longer qualify under this structure.
This is not an outright ban on InsurTech participation in insurance. Fintechs can still operate as licensed intermediaries, selling policies on behalf of insurers. What changes is the ceiling: they cannot become insurers themselves. The distinction matters because it determines who bears the underwriting risk, who holds the reserves, and who is ultimately accountable when claims go unpaid.
The regulatory logic
IRDAI reasoning rests on three pillars. First, insurance is a long-tail business. A term policy issued today may generate claims 30 or 40 years from now. VC-backed firms operate on 5-to-7-year return cycles, creating a structural misalignment between the duration of their obligations and the horizon of their investors. Second, when an InsurTech fails, policyholders bear the consequences. The promoter-led model ensures that the entity with the longest commitment to the business is also the one responsible for meeting claims. Third, IRDAI has watched global examples where rapid InsurTech scaling without adequate capital buffers led to solvency problems. The regulator is choosing stability over speed.
What this means for InsurTech innovation
The restriction creates a clear fork in the InsurTech road. Companies that want to innovate on distribution, customer experience, and digital acquisition can continue to do so as intermediaries. Companies that want to innovate on product design, underwriting, and risk appetite must now partner with or be backed by traditional promoter-led entities.
This is not necessarily anti-innovation. It is anti-fragility by design. The distinction is important: IRDAI is not saying InsurTechs cannot innovate. It is saying they cannot innovate in ways that externalize risk to policyholders while retaining the upside for investors. A VC-funded firm that underprices risk to gain market share, then exits through an IPO or sale before the claims materialize, leaves the policyholder holding a policy backed by an entity that no longer exists in its original form.
The competitive implications
For Onsurity, which has built a significant SME health insurance business through a subscription model, the restriction means its path to becoming a full-stack insurer is closed. The company must either find a promoter-led partner to anchor a manufacturing entity or accept its role as a distributor. Loop Health, which has invested heavily in wellness-integrated insurance, faces the same constraint.
For traditional insurers, the move is protective. It preserves the current market structure where manufacturing licenses are held by entities with deep capital commitments and long operational histories. The 24 licensed life insurers and 30-plus health insurers in India are overwhelmingly promoter-led, and IRDAI is ensuring that structure does not change through a backdoor capital route.
For consumers, the impact depends on execution. If the restriction leads to more InsurTechs partnering with traditional insurers rather than competing with them, product innovation could accelerate through collaboration rather than competition. If it leads to fewer distribution channels, choice could narrow. The net effect will depend on how many InsurTechs accept the distribution path and how willing traditional insurers are to integrate digital-first partners.
What to watch
The consultation process is likely to be brief. IRDAI has signaled its intent clearly, and the regulatory logic is internally consistent. Watch for two things: first, whether any existing VC-backed entities with pending manufacturing applications are grandfathered or rejected outright. Second, whether IRDAI introduces a separate category, such as a restricted insurer license, that allows limited manufacturing under tighter capital and governance requirements. The second outcome would be the real test of whether IRDAI is open to a middle path or has already decided the question.